Advertisement

The VA Co-operative Studies; The First RCTs in Cardiovascular Disease – A Tribute to Edward D. Freis

  • Vasilios PapademetriouEmail author
  • Michael Doumas
  • Costas Tsioufis
  • Kyriakos Dimitriadis
  • Charles Faselis
Chapter

Abstract

The relationship between elevated blood pressure and premature death was first demonstrated from data collected by insurance companies in the 1920s [1], and the association continued to be strengthened by data from the same source accumulated over the next 3 decades. The beneficial effects of blood pressure reduction however, remained controversial till the mid 1950s because of the luck of effective therapies and the fear of harming vital organs and actually increasing cardiovascular events with lower pressures [2]. Thus therapeutic nihilism prevailed for a long time.

Keywords

VA-Co-operative studies Randomized clinical trials Diastolic blood pressure Antihypertensive treatment Events Multi-centric studies Sustained hypertension Adherence 

References

  1. 1.
    Hunter ARO. Mortality study of impaired lives. Actuarial Soc. 1923;24:453–6.Google Scholar
  2. 2.
    Perera GA. Hypertensive vascular disease: description and natural history. J Chronic Dis. 1955;1:33–42.CrossRefGoogle Scholar
  3. 3.
    Doumas M, Papademetriou V, Douma S, et al. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens. 2010;2011:318549.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA. 1967;202:1028–34.CrossRefGoogle Scholar
  5. 5.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143–52.CrossRefGoogle Scholar
  6. 6.
    Freis E. Hypertension treatment: contributions and comments on challenges. J Clin Hypertens. 2004;6:45–6.CrossRefGoogle Scholar
  7. 7.
    Goldring W, Chasis H, Schreiner GE, Smith HW. Reassurance in the management of benign hypertensive disease. Circulation. 1956;14:260–4.CrossRefGoogle Scholar
  8. 8.
    Kempner W. Treatment of hypertensive vascular disease with rice diet. Am J Med. 1948;4:545–77.CrossRefGoogle Scholar
  9. 9.
    Goldring W, Chasis H, Fishberg AM, et al. Hypertensive vascular disease; transcription of a panel meeting on therapeutics. Bull N Y Acad Med. 1954;30:376–98.PubMedGoogle Scholar
  10. 10.
    Adson AW, McCraig W, Brown GE. Surgery in its relation to hypertension. Surg Gynecol Obstet. 1936;62:314–31.Google Scholar
  11. 11.
    Peet MM. Hypertension and its surgical treatment by supradiaphragmatic splanchnicectomy. Am J Surg. 1948;LXXV:48–68.CrossRefGoogle Scholar
  12. 12.
    Papademetriou V, Doumas M, Tsioufis C. Renal sympathetic denervation for the treatment of difficult to control or resistant hypertension. Int J Hypertens. 2011;2011:196518.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.CrossRefGoogle Scholar
  14. 14.
    Doumas M, Douma S. Interventional management of resistant hypertension. Lancet. 2009;373:1228–30.CrossRefGoogle Scholar
  15. 15.
    Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903–9.CrossRefGoogle Scholar
  16. 16.
    Doumas M, Douma S. Renal sympathetic denervation: the jury is still out. Lancet. 2010;376:1878–80.CrossRefGoogle Scholar
  17. 17.
    Tsioufis C, Dimitriadis K, Kordalis A, et al. Renal denervation therapy: can it contribute to better blood pressure control in hypertension? Curr Vasc Pharmacol. 2017;16:66–9.  https://doi.org/10.2174/15701611156661704226151649.CrossRefPubMedGoogle Scholar
  18. 18.
    Tsioufis C, Dimitriadis K, Thomopoulos C, et al. Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation. Curr Vasc Pharmacol. 2014;12:55–62.CrossRefGoogle Scholar
  19. 19.
    Faselis C, Doumas M, Kokkinos P, Tsioufis C, Papademetriou V. The role of renal nerve ablation for the management of resistant hypertension and other disease conditions: benefits and concerns. Curr Vasc Pharmacol. 2014;12:38–46.CrossRefGoogle Scholar
  20. 20.
    Raman VK, Tsioufis C, Doumas M, Papademetriou V. Renal denervation therapy for drug-resistant hypertension: does it still work? Curr Treat Options Cardiovasc Med. 2017;19:39.CrossRefGoogle Scholar
  21. 21.
    Papademetriou V, Doumas M, Anyfanti P, Faselis C, Kokkinos P, Tsioufis C. Renal nerve ablation for hypertensive patients with chronic kidney disease. Curr Vasc Pharmacol. 2014;12:47–54.CrossRefGoogle Scholar
  22. 22.
    Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation in hypertension. Curr Opin Nephrol Hypertens. 2011;20:647–53.CrossRefGoogle Scholar
  23. 23.
    Doumas M, Athyros V, Karagiannis A. Transcatheter renal sympathetic denervation: chasing a chimera or a matter of technological improvements. Cardiology. 2015;131:186–8.CrossRefGoogle Scholar
  24. 24.
    Doumas M, Lazaridis A, Papademetriou V. Renal nerve ablation for resistant hypertension: the dust has not yet settled. J Clin Hypertens. 2014;16:399–400.CrossRefGoogle Scholar
  25. 25.
    Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012;30:874–6.CrossRefGoogle Scholar
  26. 26.
    Doumas M, Faselis C, Kokkinos P, Tsioufis C, Papademetriou V. Clinical studies of renal nerve ablation. Unanswered questions for its efficacy and safety. Curr Clin Pharmacol. 2013;8:212–6.CrossRefGoogle Scholar
  27. 27.
    Petidis K, Anyfanti P, Doumas M. Renal sympathetic denervation: renal function concerns. Hypertension. 2011;58:e19.CrossRefGoogle Scholar
  28. 28.
    Worthley SG, Tsioufis CP, Worthley MI, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension. Eur Heart J. 2013;34:2132–40.CrossRefGoogle Scholar
  29. 29.
    Papademetriou V, Doumas M, Tsioufis C. Renal sympathetic denervation: hibernation or resurrection? Cardiology. 2016;135:87–97.CrossRefGoogle Scholar
  30. 30.
    Papademetriou V, Rashidi AA, Tsioufis C, Doumas M. Renal nerve ablation for resistant hypertension: how did we get here, present status and future directions. Circulation. 2014;129:1440–51.CrossRefGoogle Scholar
  31. 31.
    Bhatt DL, Kandzari DE, O’Neill WW, Symplicity HTN-3 Investigators, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.CrossRefGoogle Scholar
  32. 32.
    Papademetriou V, Tsioufis C, Doumas M. Renal denervation and Symplicity HTN-3: “Dubium sapientiae initium” (doubt is the beginning of wisdom). Circ Res. 2014;115:211–4.CrossRefGoogle Scholar
  33. 33.
    Tsioufis C. Hypertension: is the sham-procedure ‘toxic’ for renal denervation? Nat Rev Nephrol. 2014;10:186–7.CrossRefGoogle Scholar
  34. 34.
    Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomized, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160–70.  https://doi.org/10.1016/S0140-6736(17)32281-X.CrossRefPubMedGoogle Scholar
  35. 35.
    Perera GA. Antihypertensive drug versus symptomatic treatment in primary hypertension: effect on survival. J Am Med Assoc. 1960;173:11–3.CrossRefGoogle Scholar
  36. 36.
    Schoenberger JA, Stamler J, Shekelle RB, Shekelle S. Current status of hypertension control in an industrial population. JAMA. 1972;222:559–62.CrossRefGoogle Scholar
  37. 37.
    Hypertension Detection and Follow-Up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-Up Program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562–71.Google Scholar
  38. 38.
    Management Committee of the Australian National Blood Pressure Study. The Australian therapeutic trial in mild hypertension. Lancet. 1980;1:1261–7.Google Scholar
  39. 39.
    Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291:97–104.CrossRefGoogle Scholar
  40. 40.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.CrossRefGoogle Scholar
  41. 41.
    Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.CrossRefGoogle Scholar
  42. 42.
    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.CrossRefGoogle Scholar
  43. 43.
    Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Task Force Members, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.CrossRefGoogle Scholar
  44. 44.
    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.CrossRefGoogle Scholar
  45. 45.
    Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, CHEP Guidelines Task Force, et al. Hypertension Canada’s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32:569–88.CrossRefGoogle Scholar
  46. 46.
    Moser M. Salute to the icons of hypertension. J Clin Hypertens. 2004;6:8–9.CrossRefGoogle Scholar
  47. 47.
    Freis ED. The Veterans Administration cooperative study on antihypertensive agents. Implications for stroke prevention. Stroke. 1974;5:76–7.CrossRefGoogle Scholar
  48. 48.
    Freis ED. Reminiscences of the Veterans Administration Trial of the treatment of hypertension. Hypertension. 1990;16:472–5.CrossRefGoogle Scholar
  49. 49.
    Veterans Administration Cooperative Study on Antihypertensive Agents. A double blind control study of antihypertensive agents: I. Comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglionic blocking agents, chlorisondamine, mecamylamine, and pentolinium tartrate. Arch Intern Med. 1960;106:81–96.CrossRefGoogle Scholar
  50. 50.
    Veterans Administration Cooperative Study on Antihypertensive Agents. Double blind control study of antihypertensive agents: II. Further report on the comparative effectiveness of reserpine, reserpine and hydralazine, and three ganglionic blocking agents, chlorisondamine, mecamylamine, and pentolinium tartrate. Arch Intern Med. 1962;110:126–33.Google Scholar
  51. 51.
    Freis ED, Stanton JR. A clinical evaluation of veratrum viride in the treatment of essential hypertension. Am Heart J. 1948;36:723–38.CrossRefGoogle Scholar
  52. 52.
    Freis ED, Stanton JR. The hemodynamic effects of hypotensive drugs in man; dihydroergocomine. J Clin Invest. 1949;28:1387–402.CrossRefGoogle Scholar
  53. 53.
    Finnerty FA, Fries ED. Experimental and clinical evaluation in man of hexamethonium (C6), a new ganglionic blocking agent. Circulation. 1950;2:828–36.CrossRefGoogle Scholar
  54. 54.
    Freis ED, Rose JC, Higgins TF, et al. The hemodynamic effects of hypotensive drugs in man. IV. 1-Hydralazinophthalazine. Circulation. 1953;8:199–204.CrossRefGoogle Scholar
  55. 55.
    Freis ED, Wanko A, Wilson IM, Parrish AE. Treatment of essential hypertension with chlorothiazide (diuril); its use alone and combined with other antihypertensive agents. J Am Med Assoc. 1958;166:137–40.CrossRefGoogle Scholar
  56. 56.
    Freis ED, Wanko A, Wilson IM, Parrish AE. Chlorothiazide in hypertensive and normotensive patients. Ann N Y Acad Sci. 1958;71:450–5.CrossRefGoogle Scholar
  57. 57.
    Frohlich ED, Schnaper HW, Wilson IM, Freis ED. Hemodynamic alterations in hypertensive patients due to chlorothiazide. N Engl J Med. 1960;262:1261–3.CrossRefGoogle Scholar
  58. 58.
    The SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015;373:2103–16.CrossRefGoogle Scholar
  59. 59.
    SPRINT Research Group. Effects of intensive systolic blood pressure control on kidney and cardiovascular outcomes in persons without kidney disease: a secondary analysis of a randomized trial. Ann Intern Med. 2017;167:375–83.  https://doi.org/10.7326/M16-2966.CrossRefGoogle Scholar
  60. 60.
    SPRINT Research Group. Effect of intensive blood pressure treatment on patient-reported outcomes. N Engl J Med. 2017;377:733–44.CrossRefGoogle Scholar
  61. 61.
    SPRINT Research Group. Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial. Diabetes Care. 2017;40:1401–8.  https://doi.org/10.2337/dc17-0885.CrossRefGoogle Scholar
  62. 62.
    Stergiou GS, Doumas M, Kollias A, Papademetriou V. Important practice lessons from the SPRINT study beyond the blood pressure goal: all well known and now confirmed. J Am Soc Hypertens. 2016;10:613–7.CrossRefGoogle Scholar
  63. 63.
    Freis ED, Wilkins RW. The effects of pentaquine in patients with hypertension. Proc Soc Exp Biol Med. 1947;64:455–8.CrossRefGoogle Scholar
  64. 64.
    Wilkins RW. New drug therapies in arterial hypertension. Ann Intern Med. 1952;37:1144–55.CrossRefGoogle Scholar
  65. 65.
    Wilkins RW, Judson WE. The use of Rauwolfia serpentina in hypertensive patients. N Engl J Med. 1953;248:48–53.CrossRefGoogle Scholar
  66. 66.
    Freis ED, Wilson IM. Potentiating effect of chlorothiazide (Diuril) in combination with antihypertensive agents: preliminary report. Med Ann Dist Columbia. 1957;26:468–71.PubMedGoogle Scholar
  67. 67.
    Hollander W, Wilkins RW. Chlorothiazide: a new type of drug for the treatment of arterial hypertension. BMQ. 1957;8:69–75.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Vasilios Papademetriou
    • 1
    Email author
  • Michael Doumas
    • 2
  • Costas Tsioufis
    • 3
    • 4
  • Kyriakos Dimitriadis
    • 4
  • Charles Faselis
    • 2
  1. 1.Georgetown University and VA Medical CenterWashington, DCUSA
  2. 2.VA Medical Center and George Washington UniversityWashington, DCUSA
  3. 3.VA Medical Center and Georgetown UniversityWashington, DCUSA
  4. 4.1st Academic Department of CardiologyAthensGreece

Personalised recommendations